Robert G Badgett1, Valerie A Lawrence, Steven L Cohn. 1. Department of Medicine, University of Texas Health Science Center at San Antonio, and Audie L. Murphy Memorial Veterans Affairs Hospital, San Antonio, Texas, USA. rbadgett@kumc.edu
Abstract
BACKGROUND: Randomized controlled trials and meta-analyses provide conflicting guidance on the role of beta-adrenergic receptor blockers (beta-blockers) in reducing perioperative complications. We hypothesize that variability in trial results may be due in part to heterogeneous properties of beta-blockers. First, we propose that the extent of beta-blocker metabolism by cytochrome P-450 and the time available to titrate the dosage before surgery (titration time) may interact; dependence on P-450 may be most harmful when titration time is short. Second, beta-blockers vary in their selectivity for the beta-1 receptor and reduced selectivity may contribute to cerebral ischemia. METHODS: We used meta-analysis and meta-regression of existing trials to explore the role of these pharmacological properties. RESULTS: We found that both of these pharmacological factors are significantly associated with reduced efficacy of beta-blockers. CONCLUSIONS: Pharmacological properties of beta-blockers may contribute to heterogeneous trial results. Many trials have used metoprolol, which is extensively metabolized by cytochrome P450 and is less selective for the beta-1 receptor. For these two reasons, the efficacy of metoprolol to prevent perioperative cardiac complications should be compared with the efficacy of other beta-blockers.
BACKGROUND: Randomized controlled trials and meta-analyses provide conflicting guidance on the role of beta-adrenergic receptor blockers (beta-blockers) in reducing perioperative complications. We hypothesize that variability in trial results may be due in part to heterogeneous properties of beta-blockers. First, we propose that the extent of beta-blocker metabolism by cytochrome P-450 and the time available to titrate the dosage before surgery (titration time) may interact; dependence on P-450 may be most harmful when titration time is short. Second, beta-blockers vary in their selectivity for the beta-1 receptor and reduced selectivity may contribute to cerebral ischemia. METHODS: We used meta-analysis and meta-regression of existing trials to explore the role of these pharmacological properties. RESULTS: We found that both of these pharmacological factors are significantly associated with reduced efficacy of beta-blockers. CONCLUSIONS: Pharmacological properties of beta-blockers may contribute to heterogeneous trial results. Many trials have used metoprolol, which is extensively metabolized by cytochrome P450 and is less selective for the beta-1 receptor. For these two reasons, the efficacy of metoprolol to prevent perioperative cardiac complications should be compared with the efficacy of other beta-blockers.
Authors: Mostafa H El Beheiry; Scott P Heximer; Julia Voigtlaender-Bolz; C David Mazer; Kim A Connelly; David F Wilson; W Scott Beattie; Albert K Y Tsui; Hangjun Zhang; Kabir Golam; Tina Hu; Elaine Liu; Darcy Lidington; Steffen-Sebastian Bolz; Gregory M T Hare Journal: J Appl Physiol (1985) Date: 2011-07-28
Authors: Tianyi Huang; Elizabeth M Poole; A Heather Eliassen; Olivia I Okereke; Laura D Kubzansky; Anil K Sood; John P Forman; Shelley S Tworoger Journal: Int J Cancer Date: 2016-03-25 Impact factor: 7.396
Authors: Wills C Dunham; Matthew B Weinger; Jason Slagle; Mias Pretorius; Ashish S Shah; Tarek S Absi; Matthew S Shotwell; Marc Beller; Erica Thomas; Cindy L Vnencak-Jones; Robert E Freundlich; Jonathan P Wanderer; Warren S Sandberg; Miklos D Kertai Journal: J Cardiothorac Vasc Anesth Date: 2019-09-10 Impact factor: 2.628